ArticleOpen forum infectious diseases2023

Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.

Victoria G Hall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.